The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
Cholangiocarcinoma (CCA) is one of the most difficult to treat cancers, and its nature of being largely refractory to most, if not all, current treatments results in generally poor prognosis and high mortality. Efficacious alternative therapies that can be used ubiquitously are urgently needed. Usin...
Saved in:
Main Author: | Suppramote O. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/83735 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
by: Orawan Suppramote, et al.
Published: (2022) -
Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
by: Kawin Leelawat, et al.
Published: (2018) -
Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
by: Kesavapany, S., et al.
Published: (2011) -
Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions
by: Sopee Poomsawat, et al.
Published: (2018) -
Metabolomics reveals that dietary xenoestrogens alter cellular metabolism induced by palbociclib/letrozole combination cancer therapy
by: Warth, Benedikt, et al.
Published: (2020)